Topical pregabalin in the treatment of peripheral neuropathic pain

Evaluation of the effect of topical pregabalin compared to placebo in the treatment of peripheral neuropathy pain in diabetic patients: a randomized, double-blind clinical trial.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181208041882N15

Enrollment

Registered

2023-10-19

Start date

2019-06-22

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic neuropathy. Type 2 diabetes mellitus with diabetic neuropathy, unspecified

Interventions

Intervention 1: Intervention group: Patients suffering from diabetic neuropathy pain used 2% pregabalin topical cream (manufactured in Yazd Faculty of Pharmacy) topically 2.5 grams daily for 4 weeks.

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Age 18 to 80 years Neuropathy score greater than 2 based on the Michigan questionnaire

Exclusion criteria

Exclusion criteria: Severe liver and kidney failure Pregnancy Breastfeeding Hypersensitivity to pregabalin

Design outcomes

Primary

Measure	Time frame
Improvement of diabetic neuropathy pain. Timepoint: The start of treatment and the fourth week. Method of measurement: Michigan Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBehrooz Heydari

Yazd University of Medical Sciences

b.heydari@ssu.ac.ir+98 35 3820 3410

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026